

Supplemental Table.1 Combination index (CI) values of HCCLM3 and SMMC-7721 cells cotreated with soarafenib and quisinostat.

Sorafenib (μM)	Quisinostat (nM)	Effect HCCLM3	CI HCCLM3	Effect SMMC-7721	CI SMMC-7721
2.0	3.125	0.256 \pm 0.002	0.95403 \pm 0.022	0.457 \pm 0.020	0.68031 \pm 0.020
4.0	3.125	0.380 \pm 0.035	0.92971 \pm 0.035	0.577 \pm 0.061	0.63483 \pm 0.061
2.0	6.25	0.403 \pm 0.002	0.81258 \pm 0.017	0.563 \pm 0.090	0.75595 \pm 0.090
4.0	6.25	0.500 \pm 0.045	0.82425 \pm 0.045	0.709 \pm 0.039	0.55353 \pm 0.039
2.0	12.5	0.587 \pm 0.018	0.68653 \pm 0.018	0.712 \pm 0.026	0.72985 \pm 0.026
4.0	12.5	0.667 \pm 0.022	0.66308 \pm 0.022	0.850 \pm 0.048	0.41289 \pm 0.048
2.0	25.0	0.619 \pm 0.024	1.04772 \pm 0.024	0.817 \pm 0.017	0.77492 \pm 0.017
4.0	25.0	0.664 \pm 0.021	1.03215 \pm 0.021	0.86 \pm 0.088	0.64161 \pm 0.088

Supplemental Table.1 HCCLM3 and SMMC-7721 were treated with sorafenib (2 μ mol/L, 4 μ mol/L) and quisinostat (3.125-25 nmol/L) for 48 h, followed by CCK8 assay. Calculusyn software was applied to measure Combination index (CI) values. All data were obtained from experiments performed in triplicate.